(EXE) Extendicare - Ratings and Ratios
Exchange: TO • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA30224T8639
EXE: Long Term Care, Home Health Care, Nursing Services
Extendicare Inc., a prominent player in Canadas senior care sector, operates a diverse network of services tailored to the needs of an aging population. Through its subsidiaries, the company provides long-term care (LTC) services, home healthcare, and a range of therapeutic offerings, including nursing care, occupational, physical, and speech therapy, as well as assistance with daily activities. Its operations are supported by management, consulting, and other specialized services for third-party clients. The companys multi-brand approach includes Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network, each catering to different aspects of senior care. Incorporated in 1968 and headquartered in Markham, Ontario, Extendicare has established itself as a key provider in Canadas healthcare landscape. For more information, visit their website at https://www.extendicare.com.
As of the latest data, Extendicare Inc. (Ticker Symbol: EXE) is listed on the Toronto Stock Exchange (TO) under the common stock category, classified within the Health Care Facilities sub-industry. The companys market capitalization stands at 964.04 million CAD, reflecting its substantial presence in the Canadian healthcare market. Its price-to-earnings (P/E
Additional Sources for EXE Stock
EXE Stock Overview
| Market Cap in USD | 801m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception |
EXE Stock Ratings
| Growth Rating | 94.7 |
| Fundamental | 55.2 |
| Dividend Rating | 80.5 |
| Rel. Strength | 142 |
| Analysts | - |
| Fair Price Momentum | 21.50 CAD |
| Fair Price DCF | 26.70 CAD |
EXE Dividends
| Dividend Yield 12m | 20.99% |
| Yield on Cost 5y | 677.94% |
| Annual Growth 5y | 43.49% |
| Payout Consistency | 75.0% |
EXE Growth Ratios
| Growth Correlation 3m | 86.8% |
| Growth Correlation 12m | 97.1% |
| Growth Correlation 5y | 99.1% |
| CAGR 5y | 108.72% |
| CAGR/Max DD 5y | 5.24 |
| Sharpe Ratio 12m | 1.28 |
| Alpha | 136.93 |
| Beta | 0.179 |
| Volatility | 33.60% |
| Current Volume | 78.8k |
| Average Volume 20d | 169.4k |
As of April 26, 2025, the stock is trading at CAD 13.35 with a total of 78,847 shares traded.
Over the past week, the price has changed by +1.75%, over one month by +2.32%, over three months by +28.73% and over the past year by +142.30%.
Partly, yes. Based on ValueRay Fundamental Analyses, Extendicare (TO:EXE) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 55.19 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EXE as of April 2025 is 21.50. This means that EXE is currently undervalued and has a potential upside of +61.05% (Margin of Safety).
Extendicare has no consensus analysts rating.
According to ValueRays Forecast Model, EXE Extendicare will be worth about 23.2 in April 2026. The stock is currently trading at 13.35. This means that the stock has a potential upside of +73.93%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 13.5 | 1.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 23.2 | 73.9% |